Emcure signs licensing agreement with Gilead Sciences

Emcure Pharmaceuticals announced the signing of a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, part of California, US based Gilead Sciences to manufacture and supply generic versions of lenacapavir. This agreement is part of a broader effort to increase global access to lenacapavir for HIV prevention and treatment, with a focus on high-incidence, resource-limited countries.

Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries, primarily in low- and lower-middle-income regions. This strategic partnership underscores Emcure's commitment to innovative affordable global healthcare.

Commenting on the development, Satish Mehta, Managing Director and CEO, Emcure Pharmaceuticals, said, We are proud to partner with Gilead in this global initiative to expand access to critical HIV medicines. As the leader in HIV antiviral segment in covered market in India with long standing experience in supplying HIV medicines to over 100 LMIC countries, Emcure is uniquely positioned to drive impactful change in the global fight against HIV. By bringing lenacapavir to the regions that need it most, we are taking a step forward in improving health outcomes worldwide.